Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Report Summary

GlobalData, the industry analysis specialist, has released its new report, “Gastrointestinal Stromal Tumors (GIST) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global GIST therapeutics market. The report identifies the key trends shaping and driving the global GIST therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global GIST therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global GIST therapeutics market was valued at $920m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 2% over the next seven years, to reach $1,075m by 2017. This slow growth is primarily attributed to the impending patent expiry of Gleevec (imatinib), which is set to become off-patent by 2014. The patients will have access to Gleevec at much lower prices. The current competitive landscape consists of two branded drugs, Gleevec and Sutent (sunitinib).

Scope

The report provides information on the key drivers and challenges of the GIST therapeutics market. Its scope includes -

• Annualized global GIST therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such Akt activation inhibitor, multikinase inhibitors, Hedgehog signaling blockade, HSP90 inhibitors, gamma secretase inhibitors, KIT inhibitor, PDGFRA inhibitor, monoclonal antibody, mTOR inhibitor Topoisomerase II inhibitor, CDKs inhibitor and tyrosine kinase inhibitors.
• Analysis of the current and future competition in the global GIST therapeutics market. Key market players covered are Novartis AG, AB Science, Bayer Healthcare, AEterna Zentaris Inc., AROG Pharmaceuticals LLC, Astex therapeutics and OSI Pharmaceuticals.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the GIST therapeutics market.
• Analysis of key recent licensing and partnership agreements in GIST therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global GIST therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global GIST therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global GIST therapeutics market landscape? – Identify, understand and capitalize.

Table of Contents

1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5

2 Gastrointestinal Stromal Tumor (GIST) Therapeutics - Introduction 6
2.1 Overview 6
2.2 Epidemiology 6
2.3 Symptoms 7
2.4 Etiology 7
2.5 Staging of GIST 8
2.6 Diagnosis of GIST 9
2.6.1 Computed Tomography Scan (CT scan) 9
2.6.2 Barrium Swallow 9
2.6.3 Magnetic Resonance Imaging (MRI) or Positron Emission Tomography(PET scan) 9
2.6.4 Mutational Analysis 9
2.7 Treatment of GIST 9
2.7.1 Surgery 9
2.7.2 Radiation Therapy 10
2.7.3 Chemotherapy 10
2.7.4 Targeted Therapy 10
2.8 GlobalData Pipeline Report Guidance 11

3 Gastrointestinal Stromal Tumor (GIST) Therapeutics: Market Characterization 12
3.1 GIST Therapeutics Market Size (2005-2010) – Global 12
3.2 GIST Therapeutics Market Forecast (2010-2017) – Global 13
3.3 GIST Therapeutics Market Size (2005-2010) – The US 14
3.4 GIST Therapeutics Market Forecast (2010-2017) – The US 15
3.5 GIST Therapeutics Market Size (2005-2010) – France 16
3.6 GIST Therapeutics Market Forecast (2010-2017) – France 17
3.7 GIST Therapeutics Market Size (2005-2010) – Germany 18
3.8 GIST Therapeutics Market Forecast (2010-2017) – Germany 19
3.9 GIST Therapeutics Market Size (2005-2010) – Italy 20
3.10 GIST Therapeutics Market Forecast (2010-2017) – Italy 21
3.11 GIST Therapeutics Market Size (2005-2010) – Spain 22
3.12 GIST Therapeutics Market Forecast (2010-2017) – Spain 23
3.13 GIST Therapeutics Market Size (2005-2010) – The UK 24
3.14 GIST Therapeutics Market Forecast (2010-2017) – The UK 25
3.15 GIST Therapeutics Market Size (2005-2010) – Japan 26
3.16 GIST Therapeutics Market Forecast (2010-2017) – Japan 27
3.17 Drivers and Barriers for the GIST Therapeutics Market 28
3.17.1 Drivers for the GIST Therapeutics Market 28
3.17.2 Barriers for the GIST Therapeutics Market 28
3.18 Opportunity and Unmet Need Analysis 29
3.19 Key Takeaway 30

4 Gastrointestinal Stromal Tumor (GIST) Therapeutics: Competitive Assessment 31
4.1 Overview 31
4.2 Strategic Competitor Assessment 31
4.3 Product Profiles for the Major Marketed Products in the GIST Therapeutics Market 32
4.3.1 Gleevec (imatinib mesylate) 32
4.3.2 Sutent (sunitinib malate) 35
4.4 Key Takeaway 36

5 Gastrointestinal Stromal Tumor (GIST) Therapeutics: Pipeline Assessment 37
5.1 Overview 37
5.2 Strategic Pipeline Assessment 37
5.3 GIST Therapeutics Pipeline – Pipeline by Phases of Development 37
5.3.1 GIST Therapeutics – Phase III Pipeline 38
5.3.2 GIST Therapeutics – Phase II Pipeline 38
5.3.3 GIST Therapeutics – Phase I Pipeline 38
5.3.4 GIST Therapeutics – Preclinical Pipeline 39
5.3.5 Technology Trends Analytic Framework 39
5.4 GIST Therapeutics – Pipeline by Mechanism of Action 42
5.5 Molecule Profile for Promising Drugs Under Clinical Development 43
5.5.1 Masitinib 43
5.5.2 Nexavar (sorafenib) 43
5.5.3 Regorafenib (BAY 73-4506) 44
5.6 Key Takeaway 45

6 Gastrointestinal Stromal Tumor (GIST) Therapeutics: Clinical Trials Mapping 46
6.1 Clinical Trials by Country (US, EU5 and Japan) 46
6.2 Clinical Trials by Phase 47
6.3 Clinical Trials by Trial Status 48
6.4 Prominent Sponsors 49
6.5 Top Companies Participating in GIST Therapeutics Clinical Trials 51

7 Gastrointestinal Stromal Tumor (GIST) Therapeutics: Strategic Assessment 52
7.1 Key Events Impacting the Future Market 52
7.2 GIST Therapeutics: Implications for Future Market Competition 53

8 Gastrointestinal Stromal Tumor (GIST) Therapeutics: Future Players 54
8.1 Introduction 54
8.2 Company Profiles 55
8.2.1 Novartis AG 55
8.2.2 AB Science 61
8.2.3 Bayer AG 61
8.2.4 Other Companies in the GIST Therapeutics Market 66

9 GIST Therapeutics: Licensing and Partnership Deals 68

10 GIST Therapeutics: Appendix 69
10.1 Market Definitions 69
10.2 Abbreviations 69
10.3 Research Methodology 70
10.3.1 Coverage 70
10.3.2 Secondary Research 70
10.3.3 Forecasting 71
10.3.4 Primary Research 73
10.3.5 Expert Panel Validation 74
10.4 Contact Us 74
10.5 Disclaimer 74
10.6 Bibliography 75

List of Tables

Table 1: Incidence of GIST in Seven Major Markets#, 2010 6
Table 2: Occurrence Rate of Symptoms for GIST, 2010 7
Table 3: TNM Staging, GIST, 2010 8
Table 4: GIST Therapeutics Market, Global, Revenue ($m), 2005–2010 12
Table 5: GIST Therapeutics Market, Global, Forecast ($m), 2010–2017 13
Table 6: GIST Therapeutics Market, The US, Revenue ($m), 2005–2010 14
Table 7: GIST Therapeutics Market, The US, Forecast ($m), 2010–2017 15
Table 8: GIST Therapeutics Market, France, Revenue ($m), 2005–2010 16
Table 9: GIST Therapeutics Market, France, Forecast ($m), 2010–2017 17
Table 10: GIST Therapeutics Market, Germany, Revenue ($m), 2005–2010 18
Table 11: GIST Therapeutics Market, Germany, Forecast ($m), 2010–2017 19
Table 12: GIST Therapeutics Market, Italy, Revenue ($m), 2005–2010 20
Table 13: GIST Therapeutics Market, Italy, Forecast ($m), 2010–2017 21
Table 14: GIST Therapeutics Market, Spain, Revenue ($m), 2005–2010 22
Table 15: GIST Therapeutics Market, Spain, Forecast ($m), 2010–2017 23
Table 16: GIST Therapeutics Market, the UK, Revenue ($m), 2005–2010 24
Table 17: GIST Therapeutics Market, the UK, Forecast ($m), 2010–2017 25
Table 18: GIST Therapeutics Market, Japan, Revenue ($m), 2005–2010 26
Table 19: GIST Therapeutics Market, Japan, Forecast ($m), 2010–2017 27
Table 20: Sutent – GIST Efficacy Results 36
Table 21: GIST Therapeutics – Phase III Pipeline, 2011 38
Table 22: GIST Therapeutics – Phase II Pipeline, 2011 38
Table 23: GIST Therapeutics – Phase I Pipeline, 2011 38
Table 24: GIST Therapeutics – Preclinical Pipeline, 2011 39
Table 25: Nexavar Phase II Trial – Summary of Results, 2011 44
Table 26: GIST Therapeutics – Clinical Trials by Country, 2011 46
Table 27: GIST Therapeutics - Clinical Trials by Phase, 2011 47
Table 28: GIST Therapeutics - Clinical Trials by Status, 2011 48
Table 29: GIST Therapeutics - Prominent Sponsors, 2011 50
Table 30: GIST Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 51
Table 31: Novartis – Oncology Pipeline, 2011 57
Table 32: Novartis Deals, 2009-2010 58
Table 33: AB Science – Oncology Pipeline, 2011 61
Table 34: AB Science Deals, 2011 61
Table 35: Bayer AG – Oncology Pipeline, 2011 63
Table 36: Bayer AG Deals, 2009-2011 64
Table 37: GIST Therapeutics Market – Future Players 66
Table 38: GIST Therapeutics, Global, Deals 68

List of Figures

Figure 1: GIST Therapeutics Market, Global, Revenue ($m), 2005–2010 12
Figure 2: GIST Therapeutics Market, Global, Forecast ($m), 2010–2017 13
Figure 3: GIST Therapeutics Market, The US, Revenue ($m), 2005–2010 14
Figure 4: GIST Therapeutics Market, The US, Forecast ($m), 2010–2017 15
Figure 5: GIST Therapeutics Market, France, Revenue ($m), 2005–2010 16
Figure 6: GIST Therapeutics Market, France, Forecast ($m), 2010–2017 17
Figure 7: GIST Therapeutics Market, Germany, Revenue ($m), 2005–2010 18
Figure 8: GIST Therapeutics Market, Germany, Forecast ($m), 2010–2017 19
Figure 9: GIST Therapeutics Market, Italy, Revenue ($m), 2005–2010 20
Figure 10: GIST Therapeutics Market, Italy, Forecast ($m), 2010–2017 21
Figure 11: GIST Therapeutics Market, Spain, Revenue ($m), 2005–2010 22
Figure 12: GIST Therapeutics Market, Spain, Forecast ($m), 2010–2017 23
Figure 13: GIST Therapeutics Market, the UK, Revenue ($m), 2005–2010 24
Figure 14: GIST Therapeutics Market, the UK, Forecast ($m), 2010–2017 25
Figure 15: GIST Therapeutics Market, Japan, Revenue ($m), 2005–2010 26
Figure 16: GIST Therapeutics Market, Japan, Forecast ($m), 2010–2017 27
Figure 17: Opportunity and Unmet Need in the GIST Therapeutics Market, 2010 29
Figure 18: GIST Therapeutics – Strategic Competitor Assessment, 2010 31
Figure 19: Gleevec Phase III Trial Results – Progression-Free Survival 33
Figure 20: Gleevec Phase III Trial Results – Overall Response Rate 34
Figure 21: Sutent – Time to Tumor Progression in GIST Patients 36
Figure 22: GIST Therapeutics – Pipeline by Phase of Development, 2011 37
Figure 23: GIST Therapeutics – Technology Trends Analytic Framework, 2011 40
Figure 24: GIST Therapeutics – Technology Trends Analytic Framework – Description, 2011 41
Figure 25: GIST Therapeutics – Pipeline by Mechanism of Action, 2011 42
Figure 26: GIST Therapeutics – Clinical Trials by Country, 2011 46
Figure 27: GIST Therapeutics – Clinical Trials by Phase, 2011 47
Figure 28: GIST Therapeutics - Clinical Trials by Status, 2011 48
Figure 29: GIST Therapeutics - Overall Sponsors, 2011 49
Figure 30: GIST Therapeutics - Prominent Sponsors (%), 2011 50
Figure 31: GIST Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 51
Figure 32: GIST Therapeutics Market, Drivers and Restraints 2010 52
Figure 33:Implications for Future Market Competition in the GIST Therapeutics Market, 2010 53
Figure 34: GIST Therapeutics Market – Pipeline by Company, 2010 54
Figure 35: GlobalData Market Forecasting Model 73